S416
Clinical - Gynaecological
ESTRO 2026
17%). 96% patients achieved complete response. At a median follow-up of 62 months (IQR 30-93 months) the 5-year disease free survival is 88% [83%:stage 2 and 91%:stage3, p=ns, fig1b]. The 5-year overall survival (OS) is 91% [83% stage 2 and 95% stage3, p=ns, fig1a]. The overall mortality rate is 15% (13% cancer specific and 2% due to cardiovascular disease). The incidence of late toxicity was proctitis (4.5%) and cystitis (4.5%). All patients who relapsed locally (n=18) had associated systemic relapse except 2 patients who had isolated systemic relapse.
https://doi.org/10.1186/s12885-023-10517-x. Keywords: neoadjuvant CT, radical CTRT, cervical cancer
Digital Poster 1224
Impact of Molecular classification on Adjuvant Treatment in Surgically staged Endometrial cancer patients in a High Volume Tertiary Centre in LMIC Madhuri Kavikondala 1 , Harveen Kaur Gulati 2 , Haripriya Abbaraju 3 , Naga Prasanthi Akkineni 1 , Vaishnavi Pakanati 1 , Ashwini Gopal 1 , Tasneem Rushdi 1 , Sudhakar Kumar Vallurupalli 1 , Heena Kauser 1 , Rajagopalan R. 4 , Subramanyeshwar Rao T. 4 , Deleep Kumar Gudipudi 1 , Senthil J. Rajappa 3 1 Radiation Oncology, Basavatarakam Indo American Cancer Hospital and Research Institute, Hyderabad, India. 2 Pathology, Basavatarakam Indo American Cancer Hospital and Research Institute, Hyderabad, India. 3 Medical Oncology, Basavatarakam Indo American Cancer Hospital and Research Institute, hyderabad, India. 4 Surgical Oncology, Basavatarakam Indo American Cancer Hospital and Research Institute, Hyderabad, India Purpose/Objective: There has been a rapid change in the staging and adjuvant treatment protocols in Endometrial cancer patients in recent years. Incorporation of Routine molecular testing for all patients has helped us understand biology and recurrence patterns which help us tailor treatment protocols. Recent staging systems and guidelines have incorporated molecular information which have led to significant change in Adjuvant Treatment. Material/Methods: We retrospectively analyzed all patients of Endometrial cancer in our Institute who underwent surgery and Molecular testing from June 2023 to September 2025. Staging was done as per 2009 FIGO and 2023 FIGO staging systems. Adjuvant treatment
Fig 1a:Overall survival in monthsFig 1b: Disease free survival in months Conclusion: Our mature real-world results reveal that NACT followed by Radical CTRT improves overall survival in LACC and these results are comparable to prospective randomised data. This strategy is easily implementable in a LMIC and has low morbidity. References: Li J, Li Y, Wang H, Shen L, Wang Q, Shao S, et al. Neoadjuvant chemotherapywith weekly cisplatin and paclitaxel followed by chemoradiation for locallyadvanced cervical cancer. BMC Cancer 2023 Jan 14;23(1).
Made with FlippingBook - Share PDF online